NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Tarsus Pharmaceuticals Inc reported strong revenue growth in Q2 2025 driven by XDEMVY product sales.
Tarsus Pharmaceuticals achieved $102.7 million in product sales for the three months ended June 30, 2025, representing a 152% increase year-over-year. The company reported a net loss of $20.3 million and continued commercial expansion of XDEMVY for Demodex blepharitis. Operating expenses increased significantly due to selling, general and administrative costs supporting commercialization efforts.
- Product sales reached $102.7 million in Q2 2025, up 152% from $40.8 million in Q2 2024.
- Net loss improved to $20.3 million compared to $33.3 million in the prior year period.
- Approximately 91,000 bottles of XDEMVY were dispensed to patients during the quarter.
- Cash and cash equivalents stood at $96.6 million with total assets of $495.0 million as of June 30, 2025.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$103M
Revenue by segment
Tarsus · $103M total across 1 segment · Q2 2025
- Product sales$103M—100.0%
Forward guidance
The company plans to advance its pipeline including a Phase 2 study for TP-04 in ocular rosacea in the second half of 2025 and continue commercial expansion of XDEMVY.
Tailwinds
- Strong year-over-year revenue growth from XDEMVY
- Broader reimbursement coverage achieved for over 90% of covered lives
- Increased prescriber base with over 20,000 active ECPs
Headwinds
- Continued operating losses expected in the near term
- Significant increase in selling and marketing expenses
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro